15years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage.
作者： Jubilee Brown , R. Wendel Naumann , Michael J. Seckl , Julian Schink
DOI: 10.1016/J.YGYNO.2016.08.330
关键词:
摘要: Significant improvements in treatment and the understanding of gestational trophoblastic neoplasia have occurred last 15years. These diseases are almost always curable, refractory patients more options for salvage therapy. Recent epidemiology, diagnosis, cell biology resulted changes staging, advances options, opportunities fertility preservation.
gynecologiconcology-online.net
sci-hub.se 参考文章(53)
Maurício Viggiano, José Mauro Madi, Bruno Maurizio Grillo, Elza Maria Hartmann Uberti, Antonio Braga, Sue Yazaki Sun, Izildinha Maestá, Maria do Carmo Fajardo, Sérgio Lunardon Padilha, Christiani Bisinoto de Souza, Eduardo Silveira, Jurandyr Moreira de Andrade, Epidemiological report on the treatment of patients with gestational trophoblastic disease in 10 Brazilian referral centers: results after 12 years since International FIGO 2000 Consensus. Journal of Reproductive Medicine. ,vol. 59, pp. 241- 247 ,(2014)
Ernest I Kohorn, Worldwide survey of the results of treating gestational trophoblastic disease. Journal of Reproductive Medicine. ,vol. 59, pp. 145- 153 ,(2014)
John R Lurain, Julian C Schink, Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. Journal of Reproductive Medicine. ,vol. 57, pp. 219- 224 ,(2012)
N. Eagles, N.J. Sebire, D. Short, P.M. Savage, M.J. Seckl, R.A. Fisher, Risk of recurrent molar pregnancies following complete and partial hydatidiform moles Human Reproduction. ,vol. 30, pp. 2055- 2063 ,(2015) , 10.1093/HUMREP/DEV169
E.S. Newlands, P.J. Mulholland, L. Holden, M.J. Seckl, G.J. S. Rustin, Etoposide and Cisplatin/Etoposide, Methotrexate, and Actinomycin D (EMA) Chemotherapy for Patients With High-Risk Gestational Trophoblastic Tumors Refractory to EMA/Cyclophosphamide and Vincristine Chemotherapy and Patients Presenting With Metastatic Placental Site Trophoblastic Tumors Journal of Clinical Oncology. ,vol. 18, pp. 854- 854 ,(2000) , 10.1200/JCO.2000.18.4.854
P. Mapelli, G. Mangili, M. Picchio, C. Gentile, E. Rabaiotti, V. Giorgione, E. G. Spinapolice, L. Gianolli, C. Messa, M. Candiani, Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 40, pp. 505- 513 ,(2013) , 10.1007/S00259-012-2324-4
B You, R Harvey, E Henin, H Mitchell, F Golfier, P M Savage, M Tod, M Wilbaux, G Freyer, M J Seckl, Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements British Journal of Cancer. ,vol. 108, pp. 1810- 1816 ,(2013) , 10.1038/BJC.2013.123
Hys Ngan, H. Bender, J.L. Benedet, H. Jones, G.C. Montruccoli, S. Pecorelli, FIGO Committee on Gynecologic Oncol, Gestational trophoblastic neoplasia, FIGO 2000 staging and classification International Journal of Gynecology & Obstetrics. ,vol. 83, pp. 175- 177 ,(2003) , 10.1016/S0020-7292(03)90120-2
I. A. McNeish, S. Strickland, L. Holden, G. J.S. Rustin, M. Foskett, M. J. Seckl, E. S. Newlands, Low-Risk Persistent Gestational Trophoblastic Disease: Outcome After Initial Treatment With Low-Dose Methotrexate and Folinic Acid From 1992 to 2000 Journal of Clinical Oncology. ,vol. 20, pp. 1838- 1844 ,(2002) , 10.1200/JCO.2002.07.166
E. I. Kohorn, D. P. Goldstein, B. W. Hancock, S. J. Kim, J. R. Lurain, E. Newlands, J. T. Soper, L. C. Wong, Combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Heath Organization for Trophoblastic Neoplasia. Report of the Working Committee of the International Society for the Study of Trophoblastic Disease and the International Gynecologic Cancer Society International Journal of Gynecological Cancer. ,vol. 10, pp. 84- 88 ,(2000) , 10.1046/J.1525-1438.2000.00002.X